Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11870755 | 0.89 | — | — | |
| SCHEMBL11691210 | 0.81 | TSHR (0.37) | TSHRADORA2AALDH1A1 | |
| SCHEMBL11851237 | 0.80 | — | — | |
| SCHEMBL11870751 | 0.77 | — | — | |
| SCHEMBL8544588 | 0.77 | ALDH1A1 (0.50) | TSHRALDH1A1 | |
| SCHEMBL15851249 | 0.77 | TSHR (0.43) | TSHRADORA2AALDH1A1 | |
| SCHEMBL1142535 | 0.77 | TSHR (0.43) | TSHRADORA2AALDH1A1 | |
| SCHEMBL1142533 | 0.77 | TSHR (0.43) | TSHRADORA2AALDH1A1 | |
| SCHEMBL9124160 | 0.76 | THRB (0.35) | TSHR | |
| SCHEMBL5821261 | 0.75 | NAAA (0.48) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102407-A1 | TREATMENT METHODS | KHACHIGIAN LEVON MICHAEL (AU) | 2026-04-16 | — | — | US | disclosed |
| US-20240050444-A1 | TREATMENT METHODS | VASCULAR THERAPEUTICS PTY LTD (AU) | 2024-02-15 | — | — | US | disclosed |
| EP-4117655-A1 | TREATMENT METHODS | Khachigian, Levon, Michael (AU) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021184059-A1 | TREATMENT METHODS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2021-09-23 | — | — | WO | disclosed |
| EP-0230224-B1 | PROCESS FOR THE PREPARATION OF ALCOXYCARBONYL ISOCYANATES | BAYER AG (DE) | 1991-07-17 | — | — | EP | disclosed |
| US-4777283-A | Process for the preparation of alkoxycarbonyl isocyanates | BAYER AKTIENGESELLSCHAFT (DE) | 1988-10-11 | — | — | US | disclosed |
| EP-0230224-A2 | Process for the preparation of alcoxycarbonyl isocyanates | BAYER AG (DE) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050444-A1 | TREATMENT METHODS | FOSB, FOS, VCAM1 | TSHR 2518/4885ADORA2A 3287/4885ALDH1A1 2600/4885 |
| US-20260102407-A1 | TREATMENT METHODS | FOSB, VCAM1, FOS | TSHR 1510/4885ADORA2A 2719/4885ALDH1A1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.